4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 53 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $240,750 | -34.0% | 18,912 | -6.8% | 0.00% | 0.0% |
| Q2 2023 | $364,796 | +7.0% | 20,290 | +2.4% | 0.00% | 0.0% |
| Q1 2023 | $340,775 | +4.1% | 19,824 | +34.5% | 0.00% | 0.0% |
| Q4 2022 | $327,375 | +227.4% | 14,740 | +17.4% | 0.00% | – |
| Q3 2022 | $100,000 | -79.9% | 12,551 | +4.6% | 0.00% | -100.0% |
| Q4 2020 | $498,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |